Safe Administration of Ambulatory Chemotherapy Center

Abstract

Background: Previous studies of the safety of outpatient chemotherapy of severe adverse events (SAEs) and chemotherapy errors do not clearly consider the prevention. Objective:We treat approximately 2,500 outpatient-years with chemotherapy without explicit criteria in our ambulatory chemotherapy center (ACC). Our purpose is to develop safety, efficiency and risk management in our ACC by clarifying safety standards. Method, We investigated 3,067 case-years that reserved chemotherapy at ACC between Jun, 2012 and May, 2013.We have studied the effectiveness using criteria received chemotherapy in our ACC. In addition, to prevent HBV reactivation, we have tested newly-outpatients (n = 332) for serologic markers of HBV infection before chemotherapy. Results: The median age was 65 years. Treatment-related grade 3 or 4 adverse events were discontinued or deferred. HBsAg-positive, HBsAb-positive and HBcAb-positive patients were 0.9{%}(3 of 332), 13.8{%} (46 of 332) and 15{%} (3 of 332). Nobody developed HBV reactivation in our ACC. Conclusion: In this study, the chemotherapy received rate is relatively high, SAEs are low. The results suggest strategies for prevention in the outpatient chemotherapy.